Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12786MR)

This product GTTS-WQ12786MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12786MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10231MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ15877MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ3342MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ9649MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ2290MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ14118MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ1238MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW